目的：应用数据挖掘技术中关联规则、聚类等方法分析乳腺增生中药专利复方配伍规律。方法：检索治疗乳腺增生中药专利复方，排除外用中药及中西药物合用的复方。对入选的中药专利复方进行术语规范化等处理，抽取信息、建立EXCEL 表，应用数据分析软件包R2.15.2 对数据进行关联规则分析，网络分析软件Cytoscape2.8.3 聚类分析组方配伍规律。结果：195 首治疗乳腺增生的中药专利复方中，发现配伍频数较高的中药为柴胡、香附、当归、夏枯草、白芍、栝蒌等；而出现频数极低且不常用的中药为八角枫叶、白鹤草等；常用的药对为柴胡-当归、莪术-三棱、乳香-没药等；强关联规则提示以柴胡、当归等核心药物组成的逍遥散为治疗乳腺增生的基本方；聚类分析结果发现连翘-土茯苓-三桠苦-功劳木-鸡血藤等“中药社团”。结论：通过对药物频数、药对、强关联规则、药物聚类的分析，可以揭示乳腺增生组方的配伍规律，为临床优化处方、提高疗效提供参考依据。

This study was aimed to reveal the medication patterns of Chinese patent medicine in the treatment of breast hyperplasia based on association rules and clustering of data mining technology. Articles on Chinese patent medicine in the treatment of breast hyperplasia were retrieved from databases. External formulas or those mixed with western drugs were excluded. Terminologies in the selected formulas were standardized. Information was extracted to build excel tables. Association rules analysis and cluster analysis were used to reveal the medication patterns of Chinese patent medicine in the treatment of breast hyperplasia with software R2.15.2 and Cytoscape 2.8.3. The results showed that Chinese medicinals with higher frequency in 195 formulas were Radix bupleuri, Rhizoma cyperi, Chinese Angelica, Selfheal, White Peony Root, Trichosanthes kirilowii Maxim et al. Chinese medicinals with lower frequency were Chinese Alangium leaf, Rhinacanthus nasutus et al. The commonly used herbal pairs were Radix bupleuri -Chinese Angelica, Rhizoma curcumae - Rhizoma sparganii, frankincense - myrrh et al. The strong association rules indicated that Xiaoyaosan, which takes Radix bupleuri and Chinese Angelica as its core, is the key character of Chinese patent medicine in the treatment of breast hyperplasia. The cluster analysis revealed several Chinese medicine "functional modules", such as Fructus forsythiae - Rhizoma smilacis glabrae - Evodia lepta - Chinese mahonia stem - Lignum millettiae et al. It was concluded that the herbal frequency, herbal pairs, strong association rules and cluster analysis can reveal the medication patterns of Chinese patent medicine in the treatment of breast hyperplasia in order to provide reference evidences in the optimization of clinical treatment formula and improvement of therapeutic efficacy.

广西中药药效研究重点实验室（省级）开放课题（10-046-04-K1）：基于数据挖掘的古代中医妇科经带胎产用药规律研究，负责人：郭超峰。